loadpatents
name:-0.071075916290283
name:-0.029457092285156
name:-0.010551929473877
Munnich; Arnold Patent Filings

Munnich; Arnold

Patent Applications and Registrations

Patent applications and USPTO patent grants for Munnich; Arnold.The latest application filed is for "treatment and prediction of therapeutic responses in patients suffering from friedreich ataxia".

Company Profile
3.11.26
  • Munnich; Arnold - Paris FR
  • Munnich; Arnold - Paris Cedex FR
  • Munnich; Arnold - Paris Cedex 15 FR
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
Grant 11,357,778 - Legeai-Mallet , et al. June 14, 2
2022-06-14
Treatment And Prediction Of Therapeutic Responses In Patients Suffering From Friedreich Ataxia
App 20220105073 - ROTIG; Anne Agnes ;   et al.
2022-04-07
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
App 20220031696 - LEGEAI-MALLET; Laurence ;   et al.
2022-02-03
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders L
App 20200246337 - Kind Code
2020-08-06
Methods For Performing Antisense Oligonucleotide-mediated Exon Skipping In The Retina Of A Subject In Need Thereof
App 20190037583 - ROZET; Jean-Michel ;   et al.
2019-01-31
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
App 20180161327 - LEGEAI-MALLET; Laurence ;   et al.
2018-06-14
Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3
Grant 9,931,341 - Legeai-Mallet , et al. April 3, 2
2018-04-03
Methods for the treatment and diagnosis of bone mineral density related diseases
Grant 9,834,820 - Cormier-Daire , et al. December 5, 2
2017-12-05
Methods For Diagnosing And Treating Myhre Syndrome
App 20160369348 - Cormier-Daire; Valerie ;   et al.
2016-12-22
Methods For Performing Antisense Oligonucleotide-mediated Exon Skipping In The Retina Of A Subject In Need Thereof
App 20160150555 - ROZET; Jean-Michel ;   et al.
2016-05-26
Antagonist Of The Fibroblast Growth Factor Receptor 3 (fgfr3) For Use In The Treatment Or The Prevention Of Skeletal Disorders Linked With Abnormal Activation Of Fgfr3
App 20160051549 - LEGEAI-MALLET; Laurence ;   et al.
2016-02-25
Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy
App 20160032382 - Rozet; Jean-Michel ;   et al.
2016-02-04
Method For Diagnosing A Skeletal Ciliopathy
App 20150106960 - Cormier-Daire; Valerie ;   et al.
2015-04-16
Methods For The Treatment And Diagnosis Of Bone Mineral Density Related Diseases
App 20150104437 - Cormier-Daire; Valerie ;   et al.
2015-04-16
Spinal muscular atrophy diagnostic methods
Grant 8,962,269 - Melki , et al. February 24, 2
2015-02-24
Methods For Diagnosing And Treating Myhre Syndrome
App 20140308275 - Cormier-Daire; Valerie ;   et al.
2014-10-16
Spinal Muscular Atrophy Diagnostic Methods
App 20130323759 - MELKI; Judith ;   et al.
2013-12-05
Use of Deferiprone and Methods to Treat and/or Prevent Friedreich Ataxia Resulting from Intracellular Mishandling of Iron
App 20130190365 - Munnich; Arnold ;   et al.
2013-07-25
Survival motor neurons (SMN) gene: a gene for spinal muscular atrophy
Grant 8,394,932 - Melki , et al. March 12, 2
2013-03-12
Method for Diagnosing or Predicting a Non Syndromic Autosomal Recessive Optic Atrophy, or a Risk of a Non Syndromic Autosomal Recessive Optic Atrophy
App 20120110684 - Rozet; Jean-Michel ;   et al.
2012-05-03
Use of a Ginkgo biloba extract for the treatment of mitochondrial disease of genetic origin
Grant 8,097,287 - Munnich , et al. January 17, 2
2012-01-17
Survival motor Neurons (SMN) gene: a gene for spinal muscular atrophy
App 20110294226 - MELKI; Judith ;   et al.
2011-12-01
Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases
App 20100284991 - Cormier-Daire; Valerie ;   et al.
2010-11-11
Use of a Ginkgo Biloba Extract for the Treatment of Mitochondrial Disease of Genetic Origin
App 20090258095 - Munnich; Arnold ;   et al.
2009-10-15
Use Of Deferiprone And Methods To Treat And/or Prevent Friedreich Ataxia Resulting From Intracellular Mishandling Of Iron
App 20090023784 - Munnich; Arnold ;   et al.
2009-01-22
Use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
App 20070197649 - Munnich; Arnold ;   et al.
2007-08-23
Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
App 20070166737 - Melki; Judith ;   et al.
2007-07-19
Survival motor neuron (SMN) gene: a Gene for spinal muscular atrophy
App 20060089490 - Melki; Judith ;   et al.
2006-04-27
Spinal muscular atrophy diagnostic methods
Grant 7,033,752 - Melki , et al. April 25, 2
2006-04-25
Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-.kappa.B) activation
Grant 6,824,972 - Kenwrick , et al. November 30, 2
2004-11-30
Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-kappaB) activation
App 20030032055 - Kenwrick, Sue J. ;   et al.
2003-02-13
Survival motor neuron (SMN) gene: a gene for spinal muscular atrophy
Grant 6,080,577 - Melki , et al. June 27, 2
2000-06-27
Method and probes for detecting markers linked to the infantile spinal muscular atrophy locus
Grant 6,040,142 - Melki , et al. March 21, 2
2000-03-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed